TFLBUILDING

An Update on Antibody Reduction and Rejection Reversal following Bortezomib Use: A report of 52 cases across 10 centers

 

 
Based on the analysis of the 52 patient cases submitted for the Antibody Treatment Report of Clinical Transplants 2010, there is growing evidence that bortezomib is a viable option for antibody mediated rejection (AMR).

For access to complete text pdf: